口服铁剂对极低出生体重儿的促红细胞生成素治疗已足够。

Oral iron is sufficient for erythropoietin treatment of very low birth-weight infants.

作者信息

Kivivuori S M, Virtanen M, Raivio K O, Viinikka L, Siimes M A

机构信息

Hospital for Children and Adolescents, University of Helsinki, Finland.

出版信息

Eur J Pediatr. 1999 Feb;158(2):147-51. doi: 10.1007/s004310051036.

DOI:10.1007/s004310051036

PMID:10048613

Abstract

UNLABELLED

The aim of this study was to compare two different doses and means of administration of iron in recombinant human erythropoietin (rHuEPO)-treated very low birth-weight (VLBW) infants. VLBW infants (n = 41) were randomized to one of three groups. Fourteen infants were treated with rHuEPO (300 IU/kg three times a week s.c.) and oral iron (ferrofumarate, 6 mg of iron/kg per day). Another 14 infants received the same erythropoietin dose and intramuscular iron (ferroxypolymaltose, once 12 mg of iron/kg weekly). Thirteen infants were treated with the same dose of intramuscular iron but did not receive rHuEPO. After the 3-week study period, haemoglobin concentrations and reticulocyte counts were similar in the rHuEPO-treated groups and both were higher than in the group not receiving rHuEPO (P < 0.001). In both rHuEPO-treated groups the transferrin receptor concentration increased from 6.8-7.2 mg/l to 10.5-11.3 mg/l.

CONCLUSION

In erythropoietin-treated very low birth weight infants the iron need for erythropoiesis can be met by oral administration of iron.

摘要

未加标签

本研究的目的是比较重组人促红细胞生成素（rHuEPO）治疗的极低出生体重（VLBW）婴儿中两种不同剂量和给药方式的铁剂。VLBW婴儿（n = 41）被随机分为三组。14名婴儿接受rHuEPO治疗（300 IU/kg，每周皮下注射三次）和口服铁剂（富马酸亚铁，每天6 mg铁/kg）。另外14名婴儿接受相同剂量的促红细胞生成素和肌肉注射铁剂（聚麦芽糖铁，每周一次，12 mg铁/kg）。13名婴儿接受相同剂量的肌肉注射铁剂，但未接受rHuEPO。经过3周的研究期，rHuEPO治疗组的血红蛋白浓度和网织红细胞计数相似，且均高于未接受rHuEPO的组（P < 0.001）。在两个rHuEPO治疗组中，转铁蛋白受体浓度从6.8 - 7.2 mg/l增加到10.5 - 11.3 mg/l。